Aussie CRO Novotech Expands Asian Footprint With Indian ETI Joint Venture: An Interview With PharmAsia News
This article was originally published in PharmAsia News
The largest independent contract research organization in Australia, Sydney-based Novotech announced May 6 that it formed a joint venture with Bangalore-based ETI Klinical, which is part of the multinational Karle Group. With operations in Australia, New Zealand, the United States, India and South Korea, Novotech CEO Alek Safarian talked with PharmAsia News' Australia bureau about the joint venture and the company's plans to further expand its footprint in emerging markets in Asia.
You may also be interested in...
PERTH, Australia - Australia's largest independent contract research organization, Sydney-based Novotech, is expanding its operations into four new Asian markets and establishing a management hub in Kuala Lumpur, Malaysia
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).